197 related articles for article (PubMed ID: 37128274)
1. Synthesis of Amino Acids Bearing Halodifluoromethyl Moieties and Their Application to p53-Derived Peptides Binding to Mdm2/Mdm4.
Vaas S; Zimmermann MO; Klett T; Boeckler FM
Drug Des Devel Ther; 2023; 17():1247-1274. PubMed ID: 37128274
[TBL] [Abstract][Full Text] [Related]
2. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
[TBL] [Abstract][Full Text] [Related]
3. Molecular design and validation of halogen bonding orthogonal to hydrogen bonding in breast cancer MDM2-peptide complex.
Huang A; Zhou L; Zhang D; Yao J; Zhang Y
J Mol Graph Model; 2016 Nov; 70():40-44. PubMed ID: 27649550
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids.
Chee SMQ; Wongsantichon J; Siau J; Thean D; Ferrer F; Robinson RC; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2017; 12(12):e0189379. PubMed ID: 29228061
[TBL] [Abstract][Full Text] [Related]
6. The role of ETFS amino acids on the stability and inhibition of p53-MDM2 complex of anticancer p53-derivatives peptides: Density functional theory and molecular docking studies.
Soriano-Correa C; Vichi-Ramírez MM; Herrera-Valencia EE; Barrientos-Salcedo C
J Mol Graph Model; 2023 Jul; 122():108472. PubMed ID: 37086514
[TBL] [Abstract][Full Text] [Related]
7. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
8. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
[TBL] [Abstract][Full Text] [Related]
9. Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions.
Ricardo MG; Ali AM; Plewka J; Surmiak E; Labuzek B; Neochoritis CG; Atmaj J; Skalniak L; Zhang R; Holak TA; Groves M; Rivera DG; Dömling A
Angew Chem Int Ed Engl; 2020 Mar; 59(13):5235-5241. PubMed ID: 31944488
[TBL] [Abstract][Full Text] [Related]
10. Structure-based improvement of the binding affinity and recognition specificity of peptide competitors to target pediatric IL-5R/IL-5 interaction by gluing halogen bonds at their complex interface.
Chu P; Sheng Y; Shen C; Xia Y; Kong L; Sun J
J Mol Recognit; 2024 Mar; 37(2):e3070. PubMed ID: 37990248
[TBL] [Abstract][Full Text] [Related]
11. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
[TBL] [Abstract][Full Text] [Related]
12. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
13. Thermodynamic and computational studies on the binding of p53-derived peptides and peptidomimetic inhibitors to HDM2.
Grässlin A; Amoreira C; Baldridge KK; Robinson JA
Chembiochem; 2009 May; 10(8):1360-8. PubMed ID: 19408261
[TBL] [Abstract][Full Text] [Related]
14. Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions.
Su A; Wang S; Sada A; Otani Y; Zhai L; Liu X; Sayama M; Ohki R; Ohwada T
Chem Pharm Bull (Tokyo); 2019; 67(10):1139-1143. PubMed ID: 31582633
[TBL] [Abstract][Full Text] [Related]
15. Identification of small molecules affecting p53-MDM2/MDMX interaction by fluorescence polarization.
Zhang Q; Lu H
Methods Mol Biol; 2013; 962():95-111. PubMed ID: 23150440
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
[TBL] [Abstract][Full Text] [Related]
18. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
[TBL] [Abstract][Full Text] [Related]
19. Design of a novel MDM2 binding peptide based on the p53 family.
Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
[TBL] [Abstract][Full Text] [Related]
20. Halogen bonding in complexes of proteins and non-natural amino acids.
Borozan SZ; Stojanović SĐ
Comput Biol Chem; 2013 Dec; 47():231-9. PubMed ID: 24200696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
